Robin Shane Readnour, a director at An2 Therapeutics, Inc., sold 35,402 shares of the company's common stock on August 17, 2026, at a weighted average price of $6.0082 per share. The sale, totaling $212,701, comes as An2 Therapeutics trades at $5.95, near its 52-week high of $7.19, following a 418% gain over the past year. The transactions were executed in two separate sales, one for 16,696 shares and the other for 18,706 shares, pursuant to Rule 10b5-1 trading plans adopted by MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP.
Following these transactions, MGC 2018 LP indirectly holds 565,592 shares, and MGC 2018 QP indirectly holds 633,867 shares. Mr. Readnour, a member of the company's board of directors and a managing partner of MGC 2018 GP, disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest. Despite the strong price momentum, analysts maintain a consensus 'Strong Buy' rating with a price target of $9, suggesting 51% upside potential.
Recent Developments
An2 Therapeutics recently announced positive results from two studies on AN2-502998, an oral treatment for chronic Chagas disease. The company reported that a 28-day treatment led to complete parasite elimination in nonhuman primates infected with Trypanosoma cruzi. Additionally, Guggenheim initiated coverage on An2 Therapeutics with a buy rating and a price target of $9.00, highlighting the potential of the company's epetraborole as the first oral drug to control hematocrit in patients with polycythemia vera.
